The mitochondrion plays critical roles in cellular function, making it a prime organelle to target for fundamental studies, ...

Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing therapeutics targeting metalloenzymes, today announced the company will present data on its ...

FEN1 is an attractive target for development of anticancer therapeutics because it is overexpressed in many tumor types and has a large number of synthetic lethality partners including genes in ...

The FDA has cleared the investigational new drug (IND) application of LP-184 in triple negative breast cancer (TNBC) treatment – a novel small molecule advanced and developed with Lantern’s AI ...

Homologous recombination deficiency (HRD ... of patients without pathogenic mutations in known HR genes but exhibiting genomic scars indicative of HRD led to the FDA approval of the first scar-based ...

Results: Targeting PCNA suppressed DNA damage repair and ... were authenticated by STR profiling regularly every half year. Lentiviral recombination vectors of human PCNA gene (pGV492-PCNA) and its ...

Bionova Scientific, an Asahi Kasei boutique commercial-scale biologics contract development and manufacturing organization (CDMO), announced it has licensed ATUM’s proprietary Leap-In Transposase ...

As a result, the authors say, if the gene fragments are not observable prior ... "Unlike standard, tissue-based analyses of tumor cells, which can only suggest the likelihood of recurrence ...

While manipulating gene expression in brain cells holds tremendous ... Taken together, the findings of this study provide valuable insight into how brain-targeting drugs could be designed based on ...

Effective mucosal immunity in the intestine involves a fine balance between tolerance of the microbiome, recognition and elimination of pathogens, and inflammatory tissue injury. The anti-inflammatory ...